Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia

December 3, 2016, University of Texas M. D. Anderson Cancer Center
A Wright's stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikipedia

Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms (t-MNs).

A study conducted by researchers at The University of Texas MD Anderson Cancer Center revealed pre-leukemic , called clonal hematopoiesis, may predict whether patients develop t-MNs. Clonal hematopoiesis appears to function as a biomarker for patients who develop t-MNs, a leukemia recognized for its extremely poor prognosis. The study findings were published today in The Lancet Oncology and presented at the annual meeting of the American Society of Hematology in San Diego.

"Therapy-related myeloid neoplasms occur in about 5 percent of who were treated with chemotherapy and/or radiation therapy," said Andy Futreal, Ph.D., chair ad interim of Genomic Medicine. "In most cases, it is fatal, and currently there is no way to predict who is at risk or prevent it."

Being able to detect t-MNs earlier is crucial given that the disease usually occurs three to eight years following chemotherapy and/or .

"T-MNs are a problem that needs urgent attention," said Koichi Takashi, M.D., assistant professor of Leukemia and Genomic Medicine and a co-author on the Lancet Oncology paper. "Since many cancer patients are now living longer, t-MNs are an increasing concern for many cancer survivors."

Futreal's team studied 14 patients with t-MNs and found traces of pre-leukemic mutations or clonal hematopoiesis in 10. To determine if pre-leukemic mutations could reliably predict whether the patients would develop leukemia, the researchers compared prevalence of pre-leukemic mutations in the 14 patients with 54 patients who did not develop t-MNs after therapy.

"We found that prevalence of pre-leukemic mutations was significantly higher in patients who developed t-MNs (71 percent) versus those who did not (26 percent)," said Futreal. "We also validated these findings in a separate cohort of patients. Based on these findings, we believe pre-leukemic mutations may function as a new biomarker that would predict t-MNs development."

In the sample of 14 patients with t-MNs, the team looked at samples of bone marrow at the time of t-MNs development and blood samples obtained at the time of their primary cancer diagnosis.

"We found genetic mutations that are present in t-MNs leukemia samples actually could be found in blood samples obtained at the time of their original cancer diagnosis," said Takahashi. "Based on this finding, we believe the data suggest potential approaches of screening for clonal hematopoiesis in cancer patients that may identify at risk of developing t-MNs, although further studies are needed."

Explore further: Bone marrow inflammation predicts leukemia risk

Related Stories

Bone marrow inflammation predicts leukemia risk

October 3, 2016
Cancer is generally thought to arise from genetic damage within individual cells, but recent evidence has suggested that abnormal signaling in the surrounding tissue also plays an important role. In a study published September ...

Shedding light on the mutational landscape of the most common pediatric cancer

September 22, 2016
A group of researchers from Columbia University, Rutgers University, and institutions in Europe and Japan have identified genomic alterations in pediatric relapsed acute lymphoblastic leukemia (ALL) that cause both therapy ...

In highly lethal type of leukemia, cancer gene predicts treatment response

November 23, 2016
Patients with the most lethal form of acute myeloid leukemia (AML) - based on genetic profiles of their cancers - typically survive for only four to six months after diagnosis, even with aggressive chemotherapy. But new research ...

Discovery improves profiling of AML patients for targeted therapies

July 11, 2016
Testing for DNMT3A mutations in FLT3-ITD subgroup of AML patients at the point of diagnosis and post-chemotherapy could improve treatment and predict chances of relapse and survival rates respectively

Relapse, poor survival in leukemia linked to genetic mutations that persist in remission

August 25, 2015
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations - detected after initial treatment with chemotherapy - are associated with an increased risk of relapse and ...

Prevalence of estrogen receptor mutations in patients with metastatic breast cancer

August 11, 2016
A new study published online by JAMA Oncology examines the prevalence and significance of estrogen receptor mutations in patients with metastatic breast cancer.

Recommended for you

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.